Korean Drug

At a glance

Korean Drug filed 24 disclosures in the last 12 months, including 4 buyback. The most recent key filing was on May 18: Plans to dispose of 123 sh of treasury stock, May 19 to Jun 19.

Revenue for 2025 was ₩62.5B, down 14.4% on 2024. Operating margin was 11.1% against 12.5% a year earlier. Debt was 14% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩30.9B and operating profit of ₩3.8B.

The 2025 annual report lists 238 employees with an average tenure of 9.2 years and average pay of ₩55.8M, #1404 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩217.3M each on average. It paid ₩180 per common share in cash dividends, against ₩160 a year earlier (+12.5%). 박상훈 and related parties held 50.19% at year end.

From the 2025 annual report

Staff: 238 (141 men, 97 women), of whom 13 on fixed-term contracts. Total pay for the year: ₩13.3B. Directors and auditors: 5, paid ₩1.1B in total.

Dividends (common shares)

Largest shareholder

박상훈 holds 38.84%; with 4 related parties the group holds 50.19% of common shares at year end.

Auditor: 대성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary